Mediaite on MSN
Caller identifying as a Defense Department lawyer tells Dan Abrams staffers are hunkering down under Hegseth
"Most of us are just hunkering down and waiting for the storm to pass," the self-described senior Department of Defense lawyer told Dan Abrams. The post Caller Identifying as a Defense Department ...
Idaho Public Press on MSN
Trump brought back the 'Department of War.' The legal name still says Defense.
Trump signed an executive order restoring the Department of War name as a secondary title. Here's why the legal name still ...
The US military’s full embrace of high-energy laser weapons may depends on how easy they are for the average service member ...
In a third attempted prosecution, the department alleges the former FBI director leaked national-defense information 10 years ...
The Defense Department inked a $150 million conditional loan commitment with reusable-rocket company Stoke Space Technologies, giving the startup a capital injection as the U.S. aims to boost its ...
The Pentagon is pressing Congress to keep measures in the annual defense policy bill that would formally authorize the name change from Department of Defense to Department of War. “President Donald ...
The Trump administration has just charged James Comey for a third time. The Department of Justice alleged that the former FBI director leaked national defense information 10 years ago, according to ...
OmniSync Incorporated today announced that the Department of War adaptation of its TurboInnovate platform, an AI-powered innovation market intelligence software, has been successfully deployed in an ...
Comey was last charged in April for allegedly threatening President Donald Trump’s life in a social media post.
Comey, an outspoken critic of Donald Trump, accused of leaking information related to US national defense ...
Former FBI Director James Comey has been charged with unlawfully sharing national defense information and conspiring to leak ...
The new pact will see Regeneron provide doses of the drug—which includes atoltivimab, maftivimab and odesivimab-ebgn—through 2031. In exchange, the company is in line to receive roughly $270 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results